KRAS mutations Yakup Ergün

Yakup Ergün: With KRAS mutations now targetable, I was reminded of our research on backbone chemotherapy selection

Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X about a paper he co-authored with colleagues published in Expert Review of Molecular Diagnostics:

“In the present day, when we have learned that KRAS mutations can be targeted, I was reminded of our research on the selection of backbone chemotherapy.

We had found that irinotecan was superior to oxaliplatin in patients with codon 12 mutations in metastatic KRAS-mutant CRC.”

“KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer”

Authors: Yakup Ergun, Yusuf Acikgoz, Oznur Bal, Gokhan Ucar, Merve Dirikoc, Eda Caliskan Yildirim, Nadiye Akdeniz, Dogan Uncu.

Yakup Ergün: With KRAS mutations now targetable, I was reminded of our research on backbone chemotherapy selection

More posts featuring Yakup Ergün.

cancer CRC Dogan Uncu Eda Caliskan Yildirim Gokhan Ucar KRAS-mutant CRC Merve Dirikoc Nadiye Akdeniz OncoDaily Oncology Oznur Bal Yakup Ergün Yusuf Acikgoz